Exhibit 99.1 Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Submitted for Presentation at the American Society of Hematology ...

U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Submitted for Presentation at the American Society of Hematology (ASH) Annual Meeting First Patient Dosed in the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin ...

The stock rallied as optimism grew over the company's promising pipeline of gene editing therapies, which have been developed based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases. Several clinical milestones are expected later in 2024. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical researc ...

BEAM stock enjoys several positive technical factors that warrant closer investigation. First, Barchart identified the biotech enterprise as a possible J-Hook pattern candidate. The J-Hook is a sinusoidal chart pattern that has attracted attention recently in the field of technical analysis. Featuring an up-down, up-down cycle, at the end of the defined "J" pattern, there's a solid possibility that the asset in question could shoot decisively higher. Barchart only identifies viable candidates after they mee ...

Vertex Pharmaceuticals (VRTX) Source: Pavel Kapysh / Shutterstock.com Vertex Pharmaceuticals (NASDAQ:VRTX) stands out as one of the most seasoned players in the biotech space. Unlike the sea of start-ups in the gene editing field, Vertex boasts a rich legacy in the pharma space, empowering it to leverage its massive financial resources. In recent years, we've seen it dabbling into new areas like gene editing, targeting inflammatory and autoimmune disorders along with certain cancers. Moreover, it collaborat ...

Core Viewpoint - Beam Therapeutics is undergoing a leadership transition with the departure of its CFO, Terry-Ann Burrell, while continuing to advance its gene editing therapies and clinical studies [2][11][12]. Company Developments - Shares of Beam Therapeutics have decreased by 5.8% year to date, compared to a 2.7% decline in the industry [1]. - The company is actively searching for a new CFO following the resignation of Terry-Ann Burrell, who has been pivotal in the company's growth [2][11]. - Burrell will transition to a role as vice chairman of investment banking at JPMorgan Chase [12]. Clinical Pipeline - Beam Therapeutics is progressing with its gene editing therapies based on proprietary base editing technology, focusing on hematology, immunology/oncology, and genetic diseases [13]. - The BEACON study has completed dosing and engraftment for three patients, with data from multiple patients expected in the second half of 2024 [4]. - The company has initiated a phase I/II study for BEAM-302 targeting alpha-1 antitrypsin deficiency, aimed at determining the optimal dosage [5]. - An investigational new drug (IND) application for BEAM-301, targeting glycogen storage disease 1a, is expected to be filed soon [6][16]. - The leading candidate, BEAM-101, is being evaluated in the BEACON study for treating sickle cell disease [14]. Market Position - Beam Therapeutics currently holds a Zacks Rank of 2 (Buy) [18]. - The company is positioned to achieve clinical milestones later in the year, which may influence its long-term growth trajectory [17].

"Terry-Ann has been an invaluable member of our team over the last five years, and her leadership was instrumental in the success of our IPO, the build-out of our finance and corporate affairs functions, and the development of Beam's organization and culture," said John Evans, chief executive officer at Beam. "During her tenure, we have successfully raised significant capital to invest in our innovative platform technologies, our manufacturing capabilities, and now our rapidly growing clinical and research ...

Here are some reasons why investors should consider betting on Beam Therapeutics stock. Hematology Program Picking Up Pace: The company is pursuing an ex vivo, autologous transplant-based approach for SCD and beta-thalassemia. It is currently developing BEAM-101 in the phase I/II BEACON study for SCD. Dosing and engraftment for the three patients in the sentinel cohort of the BEACON study have been completed. Data from multiple patients in the study is expected in the second half of 2024. Image Source: Zack ...

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. As such, the Zacks rating upgrade for Beam Therapeutics is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. The change in a company's future earnings potential, as reflected in earnings estimate revisi ...

分组1: VICI Properties - VICI stock trades at a P/E ratio of 11x, significantly below the S&P 500 average of 30x [1] - Despite a 13% year-to-date decline, all 21 analysts recommend buying VICI shares due to consistent revenue growth [1] - VICI Properties is a REIT investing in casinos and hospitality, offering a 6% dividend yield and strong sales with a profit margin of 70.1% [18] 分组2: Beam Therapeutics - Beam Therapeutics develops precision genetic medicines and is working on therapies for serious diseases, including sickle cell disease [6][7] - The company has $1.09 billion in cash reserves, sufficient to fund operations through 2027 [7] - Analysts recommend purchasing BEAM stock with an average price target of $48.64, indicating over 110% upside potential [7] 分组3: Booking Holdings - Booking Holdings is the leading online hotel and travel booking company, owning major websites like booking.com and Kayak [8] - Gross bookings have grown 24% over the last year, with net income nearly doubling from the prior year [9] - The BKNG share price has increased 44% over the last year, with earnings growing at 191.7% year-over-year [16][17]